1Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection[J]. N Engl J Med, 1998, 338（13）: 853-860.
2Grulich AE. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy[J]. J Acquir Immune Defic Syndr, 1999, 21(Suppl 1): S27-S30.
3Kovacs J, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection[J]. N Engl J Med, 2000, 342(19): 1416-1429.
4Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression:results from the EuroSIDA study[J]. Ann Intern Med, 1999, 130（7）: 570-577.
5Nielsen H, Kvinesdal B, Benfield T, et al. Rapid loss of specific antibodies after pneumococcal vaccination in patients with human immunodeficiency virus-1 infection[J]. Scand J Infect Dis, 1998, 30（6）: 597-601.
6Tasker SA, Treanor JJ, Paxton WB, et al. Efficacy of influenza vaccination in HIV-infceted persons: a randomized ,double-blind, placebo-controlled trial[J]. Ann Intern Med, 1999, 131（6）: 430-433.
7Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabution, or both[J]. N Engl J Med, 1996, 335（6）: 392-398.
8McKinsey DS, Wheat LJ, Cloud GA, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study[J]. Clin Infect Dis, 1999, 28（5）: 1049-1056.
9Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy[J]. N Engl J Med, 1999, 340（17）: 1301-1306.
10Kirk O, Lundgren JD, Pedersen C, et al. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy[J]. AIDS, 1999,13（13）: 1647-1651.
